CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market Expected to Witness Significant Expansion Through 2034, According to DelveInsight

Image: http://www.abnewswire.com/pressreleases/wp-content/uploads/2026/06/2026
DelveInsight's "CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast-2034" report delivers a comprehensive understanding of CAR T-Cell Therapy for Non-Hodgkin's Lymphoma, including historical and forecasted epidemiology trends as well as market dynamics across the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market

The newly published healthcare market report provides an extensive evaluation of CAR T-Cell Therapy for Non-Hodgkin's Lymphoma, offering valuable insights into market trends, disease prevalence, and the evolving treatment landscape. The report highlights key market statistics, including current and projected market size, while assessing the clinical effectiveness and developmental progress of emerging CAR T-cell therapies. It also presents a detailed overview of ongoing and future clinical trials that are expected to influence the future treatment paradigm for Non-Hodgkin's Lymphoma. This report serves as an important resource for stakeholders seeking to understand the changing market environment and therapeutic innovations in the CAR T-cell therapy space.

To gain deeper insights into the CAR T-Cell Therapy for Non-Hodgkin's Lymphoma market outlook, treatment scenario, epidemiology trends, and drug uptake, click here; CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market Forecast https://www.delveinsight.com/sample-request/car-t-cell-therapy-for-non-hodgkins-lymphoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr

Some of the key facts of the CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market Report:

- The CAR T-Cell Therapy for Non-Hodgkin's Lymphoma market is projected to expand at a notable CAGR during the forecast period from 2020 to 2034.

- In November 2024, Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage biotechnology company focused on next-generation CAR T-cell therapies for solid tumors and hematologic malignancies, announced that preliminary clinical data from the Phase 1-2 trial of IMPT-314 in large B-cell lymphoma would be presented at the 66th American Society of Hematology (ASH) Annual Meeting held in San Diego, California, from December 7-10, 2024. The presentation was delivered by Dr. Sarah M. Larson, Associate Professor at the David Geffen School of Medicine at UCLA. IMPT-314 is a dual-targeting CD19/CD20 CAR T-cell therapy under development for aggressive B-cell Non-Hodgkin's Lymphoma.

- In May 2024, Verismo Therapeutics received FDA IND clearance for SynKIR-310 for the treatment of relapsed/refractory B-cell NHL.

- In March 2024, Bristol Myers Squibb announced that the US FDA approved BREYANZI as the first CAR T-cell therapy indicated for adult patients with relapsed or refractory CLL or SLL.

- Key companies involved in the CAR T-Cell Therapy for Non-Hodgkin's Lymphoma market include Hrain Biotechnology, Lazaros Lekakis, Beijing Immunochina Medical Science, Juno Therapeutics, Gilead Sciences, Novartis, Bristol Myers Squibb, Allogene Therapeutics, Miltenyi Biomedicine, Autolus Therapeutics, Tessa Therapeutics, and others.

- Key therapies in development and commercialization include Human CD19Targeted T Cells Injection, Mosunetuzumab, IM19 CAR-T Cells, lisocabtagene maraleucel, YESCARTA, KYMRIAH, BREYANZI, Cemacabtagene ansegedleucel, Rapcabtagene autoleucel (YTB323), Zamtocabtagene autoleucel, AUTO4, CD30.CAR-T, and others.

- The CAR T-Cell Therapy for Non-Hodgkin's Lymphoma market is anticipated to grow substantially owing to the rising prevalence of NHL and increasing awareness regarding advanced immunotherapies. In addition, the introduction of multiple pipeline candidates across different stages of development is expected to significantly transform market dynamics during the forecast timeline.

- According to DelveInsight's analysis, approximately 125,900 NHL patients across the 7MM were considered eligible for CAR-T therapy in 2023.

- Diffuse Large B-Cell Lymphoma (DLBCL) represented the most prevalent subtype of Non-Hodgkin's Lymphoma within the EU4 and the UK, accounting for nearly 32,400 cases in 2023.

- Japan recorded approximately 23,700 incident cases of NHL among selected subtypes in 2023.

CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Overview

Chimeric Antigen Receptor (CAR) T-cell therapy is a groundbreaking immunotherapy approach designed to treat certain forms of Non-Hodgkin's Lymphoma. The treatment involves genetically engineering a patient's own T-cells to express receptors capable of recognizing and attacking malignant B-cells commonly associated with NHL. Once modified, these CAR T-cells are reinfused into the patient's body, where they target and eliminate lymphoma cells. CAR T-cell therapy has demonstrated encouraging outcomes, especially among patients with relapsed or refractory aggressive NHL, and is widely regarded as a major advancement in the field of cancer immunotherapy due to its highly targeted mechanism of action.

Get a free sample of the CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/sample-request/car-t-cell-therapy-for-non-hodgkins-lymphoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr

CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Epidemiology

The epidemiology section offers detailed insights into historical, current, and forecasted epidemiological trends across the seven major markets (7MM) from 2020 to 2034. It assists in understanding the factors contributing to current and future disease trends through the analysis of published studies and expert opinions from key opinion leaders. The section also provides a detailed evaluation of the diagnosed patient pool and anticipated future developments.

CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Epidemiology Segmentation:

The report provides epidemiological analysis for the 2020-2034 study period across the 7MM, segmented into:

- Total prevalence of CAR T-Cell Therapy for Non-Hodgkin's Lymphoma- Prevalent cases categorized by severity- Gender-specific prevalence of CAR T-Cell Therapy for Non-Hodgkin's Lymphoma- Diagnosed cases of episodic and chronic CAR T-Cell Therapy for Non-Hodgkin's Lymphoma

Download the report to explore the factors influencing CAR T-Cell Therapy for Non-Hodgkin's Lymphoma epidemiology trends @ CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Epidemiology Forecast [https://www.delveinsight.com/sample-request/car-t-cell-therapy-for-non-hodgkins-lymphoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr]

CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Drugs Uptake and Pipeline Development Activities

The drug uptake section evaluates the adoption trends of recently launched therapies as well as potential upcoming treatments expected to enter the CAR T-Cell Therapy for Non-Hodgkin's Lymphoma market during the forecast period. The analysis includes market uptake by therapies, patient adoption rates, and sales performance of individual products.

Additionally, the therapeutic assessment section identifies therapies expected to witness the fastest uptake and explains the factors supporting their increased adoption. The report also compares therapies based on market share performance.

Furthermore, the report provides comprehensive insights into ongoing pipeline development activities, highlighting therapeutic candidates across different stages of development along with the companies involved in their advancement. It also evaluates recent strategic developments such as partnerships, acquisitions, mergers, licensing agreements, and patent-related activities associated with emerging therapies.

CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Therapies and Key Companies

- Human CD19Targeted T Cells Injection: Hrain Biotechnology- Mosunetuzumab: Lazaros Lekakis- IM19 CAR-T Cells: Beijing Immunochina Medical Science- lisocabtagene maraleucel: Juno Therapeutics- YESCARTA: Gilead Sciences- KYMRIAH: Novartis- BREYANZI: Bristol Myers Squibb- Cemacabtagene ansegedleucel: Allogene Therapeutics- Rapcabtagene autoleucel (YTB323): Novartis- Zamtocabtagene autoleucel: Miltenyi Biomedicine- AUTO4: Autolus Therapeutics- CD30.CAR-T: Tessa Therapeutics

Explore additional therapies expected to capture significant CAR T-Cell Therapy for Non-Hodgkin's Lymphoma market share @ CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Treatment Landscape [https://www.delveinsight.com/sample-request/car-t-cell-therapy-for-non-hodgkins-lymphoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr]CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market Drivers

- Advancements in immunotherapy technologies- Strong efficacy in relapsed/refractory NHL- Increasing number of FDA approvals- Rising incidence of Non-Hodgkin's Lymphoma- Ongoing clinical trials and research initiatives- Encouraging patient treatment outcomes

CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market Barriers

- High treatment expenses- Limited patient accessibility- Complex manufacturing and supply chain requirements- Risk of treatment-related side effects- Reimbursement and coverage challenges- Uncertainty regarding long-term efficacy and safety

Scope of the CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market Report

- Study Period: 2020-2034- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]- Key Companies: Hrain Biotechnology, Lazaros Lekakis, Beijing Immunochina Medical Science, Juno Therapeutics, Gilead Sciences, Novartis, Bristol Myers Squibb, Allogene Therapeutics, Miltenyi Biomedicine, Autolus Therapeutics, Tessa Therapeutics, and others- Key Therapies: Human CD19Targeted T Cells Injection, Mosunetuzumab, IM19 CAR-T Cells, lisocabtagene maraleucel, YESCARTA, KYMRIAH, BREYANZI, Cemacabtagene ansegedleucel, Rapcabtagene autoleucel (YTB323), Zamtocabtagene autoleucel, AUTO4, CD30.CAR-T, and others- Therapeutic Assessment: Current marketed and emerging therapies- Market Dynamics: Drivers and barriers influencing market growth- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, and market entry strategies- Unmet Needs, KOL perspectives, analyst insights, market access, and reimbursement analysis

About DelveInsight

DelveInsight is a leading healthcare business consulting and market research firm specializing in the life sciences sector. The company supports pharmaceutical and biotechnology organizations with comprehensive end-to-end market intelligence solutions aimed at enhancing business performance.

DelveInsight also offers strategic healthcare consulting services that assist organizations in accelerating growth opportunities, analyzing market trends, and overcoming business challenges through practical and data-driven approaches.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email [http://www.abnewswire.com/email_contact_us.php?pr=car-tcell-therapy-for-nonhodgkins-lymphoma-market-expected-to-witness-significant-expansion-through-2034-according-to-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/sample-request/car-t-cell-therapy-for-non-hodgkins-lymphoma-market

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.